Long-term Efficacy and Safety of Kang'ai Injection Combined with Docetaxel and Prednisone in the Treatment of Hormone Refractory Prostate Cancer
WU Jun-ping
CHEN Ting-ting
SONG Wen-hua
YANG Guo-dong
MA Wen-bo
Abstract：Objective To investigate the long-term efficacy and safety of Kang'ai injection combined with Docetaxel and prednisone in the treatment of hormone refractory prostate cancer.Methods From January 2010 to May 2012,178 cases of hormone refractory prostate cancer treated in our hospital were randomly divided into observation group and control group,with 89 cases in each group.Both groups were treated with dossier and prednisone,and on this basis,the observation group was given kangai injection.The two groups were compared with respect to short-term efficacy,the international prostate symptoms score (IPSS),quality of life (QOL) scores,five-year survival rates,five-year rehospitalization and adverse reactions.Results Total effective rates,tumor control rate,five-year survival rate and five-year rehospitalization in observation group and control group were 88.76％ vs 70.69％,94.38％ vs 80.90％,35.96％ vs 22.47％ and 46.07％ vs 67.42％,respectively.The difference was statistically significant (P ＜ 0.05).The IPSS and QOL scores were significantly decreased in both groups after treatment (P ＜0.05),as compared with those prior to treatment.Compared with the control group,the IPSS and QOL scores were remarkably decreased in observation group after treatment (P ＜ 0.05).There was no statistically significant difference between the two groups in terms of adverse reactions (P ＞ 0.05).Conclusion The clinical therapeutic effects of kang'ai injection on the treatment of hormone refractory prostate cancer were satisfactory without serious adverse reactions.
Keywords：Prostatic neoplasmsComparative effectiveness researchAdverse drug reaction
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 81-84 )